20 articles
The FDA will convene advisory panels in July 2025 to reconsider whether compounding pharmacies can legally produce certain popular peptides removed from approved lists in 2023.
New AI-discovered peptide mimics Ozempic's weight loss effects but targets only the brain's appetite center, avoiding nausea and muscle loss.
BioAge's oral drug BGE-102 cut a key cardiovascular risk biomarker by up to 86% in obese patients, rivaling higher doses at just 60mg daily.
Vasa Therapeutics advances VS-214, a peptide targeting poor limb circulation, toward first human trials in 2026 — addressing a massively underserved condition.
BioAge's oral drug BGE-102 dramatically reduced hsCRP and IL-6 in obese participants with elevated inflammation, with a strong safety profile.
Antag Therapeutics reports AT7687 is well tolerated in humans and drives weight loss in primates when combined with cagrilintide.
BioAge's BGE-102 enters Phase 2 with dramatic Phase 1 CRP reductions, targeting cardiovascular risk through inflammasome blockade.
BioAge's oral NLRP3 inhibitor BGE-102 cut hsCRP by ~85% in weeks, signaling a potential breakthrough in treating chronic inflammation at scale.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
A new GLP-1 therapy engineered to cross the blood-brain barrier enters Phase II trials, targeting cognitive decline in Parkinson's and Alzheimer's.
Preclinical data show ACD137 rivals leading anti-NGF antibody Tanezumab for pain relief while also offering anti-inflammatory and joint-protective effects.
Cambrian Bio's ATX-304 combines AMPK and mitochondrial activation in a pill form, with Phase 1b data in prediabetic obese adults due this week.
FDA will reconsider allowing compounding pharmacies to produce 12 peptides removed in 2023, following advocacy from health officials.
Cambrian Bio's ATX-304 reduced liver fat, visceral fat, and raised resting metabolic rate by 8% in a Phase 1b trial of adults with prediabetes.
Matter Bio files first IND for Listeria-based therapy targeting pancreatic cancer, merging oncology and longevity science.
NorthStrive Biosciences patents two muscle-preserving compounds targeting sarcopenia and GLP-1-related muscle loss in humans.
NorthStrive Biosciences files a patent for EL-22, a myostatin-targeting probiotic designed to prevent muscle loss from GLP-1 drugs and aging.
BioNTech reports positive Phase 2 results for HER2-targeted cancer therapy, with FDA filing planned to compete with existing treatments.
A phase III trial shows saroglitazar helped 57% of primary biliary cholangitis patients achieve biochemical response vs just 10% on placebo.
Pegsebrenatide, a long-acting GLP-1 receptor agonist, is now in human trials targeting neurodegeneration in progressive MS — with broad longevity implications.
